In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process.
Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance.
Putting the dynamics into compound profiling: using kinetic assays to shape drug discovery, will take place on 10 December at 3PM (BST). It is hosted by DDW and supported by SPT Labtech. It will be delivered by Excellerate Bioscience, an innovative contract research organisation known for its excellence in molecular and cellular pharmacology.
Who should attend
This free webinar will be of value to:
- Academic and commercial researchers
- Drug discovery research scientists
- Assay developers
- Screening scientists
What you will learn
- How association and dissociation rate constants describe compound binding kinetics
- The potential clinical benefits of optimising kinetic constants when compound profiling
- The wider relevance of signalling kinetics in determining therapeutic effects
- Methods to implement binding and signalling kinetic screening
With 25 years’ experience in the molecular pharmacology of receptors and other drug targets, Dr Holliday will share his expertise with the DDW audience.
“Using case studies from the CNS and respiratory disease areas, I will highlight the benefits of optimising binding on and off rates for duration of action and generation of kinetic selectivity, together with improved inhibitor and antagonist effects,” he said.
In vitro early-stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay.
However, in vivo, drug action occurs within a highly dynamic system where kinetic profiles for binding and signalling may be key influences on efficacy and selectivity. Imaging technologies now allow compound kinetic parameters to be mapped and optimised in medium throughput, homogeneous assay formats, suitable for integration into a lead optimisation screening cascade.
Date: 10 December 2020
Time: 3pm UK BST
Cost: Free-to-attend (participation subject to approval)
Click here to register for free